“These data presented at the COVID-19 virtual conference provide additional insight into the use of remdesivir in specific patient populations, including those who may be susceptible to higher rates of COVID-19 infection, as well as others who are particularly vulnerable, including children. and pregnant and postpartum women, “added Parsey.
Gilead’s shares rose 2% on Friday morning after the release of the change of hands to $ 76.23 each, a move that would bring the stock gain since the start of the year to around 17%.
Remdesivir was first designed to fight the Ebola virus and was authorized by the United States Food and Drug Administration in early spring under rules allowing patients to use unapproved drugs in life-threatening situations. life threatening when all other options have been exhausted.
Gilead stated at the time that “positive data from the National Institute of Allergy and Infectious Diseases’ remdesivir study” indicated that treatment had “met its primary endpoint” and also noted that its own study found that nearly two-thirds of the approximately 400 patients with severe coronavirus using remdisivir were discharged from hospital after using treatment early, better than those who received the drug at a later stage.
Studies contradicted information released on the World Health Organization website last month, suggesting that remdesivir had little success in a China-based study that was discontinued after authorities said it there were not enough patients enrolled.